Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases
Sign Up to like & getrecommendations! Published in 2019 at "Case Reports in Gastroenterology"
DOI: 10.1159/000502605
Abstract: Ibrutinib, an irreversible Bruton’s tyrosine kinase inhibitor, is an effective treatment for Waldenström’s macroglobulinemia, chronic lymphocytic leukemia, and several other types of lymphoma. Studies prior to FDA approval in 2015 failed to demonstrate any hepatotoxicity.… read more here.
Keywords: hepatotoxicity due; ibrutinib; due ibrutinib; hepatotoxicity ... See more keywords